We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $48.81, moving +2.61% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.72%. Elsewhere, the Dow saw an upswing of 0.48%, while the tech-heavy Nasdaq appreciated by 1.16%.
The company's stock has dropped by 18.07% in the past month, falling short of the Medical sector's loss of 7.29% and the S&P 500's loss of 4.99%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.15 per share, which would represent year-over-year growth of 27.22%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.32 million, up 741.03% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$4.85 per share and a revenue of $39.15 million, demonstrating changes of +25.04% and +1015.33%, respectively, from the preceding year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.35% lower. At present, CRISPR Therapeutics AG boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 150, finds itself in the bottom 39% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $48.81, moving +2.61% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.72%. Elsewhere, the Dow saw an upswing of 0.48%, while the tech-heavy Nasdaq appreciated by 1.16%.
The company's stock has dropped by 18.07% in the past month, falling short of the Medical sector's loss of 7.29% and the S&P 500's loss of 4.99%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.15 per share, which would represent year-over-year growth of 27.22%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.32 million, up 741.03% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$4.85 per share and a revenue of $39.15 million, demonstrating changes of +25.04% and +1015.33%, respectively, from the preceding year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.35% lower. At present, CRISPR Therapeutics AG boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 150, finds itself in the bottom 39% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.